Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jay Duker Insider Profile
4 Followers
Jay Duker, Director at Carisma Therapeutics, holds 95.21K shares in EyePoint Pharmaceuticals (Ticker: EYPT), holds 40.00K shares in Carisma Therapeutics (Ticker: CARM).
Jay Duker has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Jay Duker holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Apr 03, 2019 - Apr 03, 2020
Return:-60.20%
The most profitable trade made by Jay Duker
Jay Duker's Trading History
Carisma Therapeutics
Jun 24, 2022
Director
Uninformative Buy
―
$17.60K
EyePoint Pharmaceuticals
Jan 07, 2025
President & CEO, Director
Uninformative Buy
292.41K
$712.14K
List of latest transactions for each holding click on a transaction to see Jay Duker's performance on stock
You May Also Like
Jay Duker insider profile FAQ
What is the percentage of profitable transactions made by Jay Duker?
The percentage of profitable transactions made by Jay Duker is ―.
What is the average return per transaction made by Jay Duker?
The average return per transaction made by Jay Duker is ―.
What stocks does Jay Duker hold?
Jay Duker holds: CARM, EYPT stocks.
What was Jay Duker’s latest transaction?
Jay Duker latest transaction was an Uninformative Buy of $292.41K.
What was Jay Duker's most profitable transaction?
Jay Duker’s most profitable transaction was an Informative Buy of EYPT stock on April 3, 2019. The return on the trade was -60.20%.
What is Jay Duker's role in Carisma Therapeutics?
Jay Duker's role in Carisma Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.